Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients

Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients

Posted by  | treatment

In a head-to-head comparison between the immunotherapy drug pembrolizumab and standard chemotherapy as a first-line therapy for advanced nonsmall cell lung cancer, patients taking pembrolizumab had a 50 percent greater drop in the risk of death or disease progression and a four-month greater increase in progression-free survival compared with those who took chemotherapy. A report on(...)

Studies track how the immune system responds to tumors

Studies track how the immune system responds to tumors

Posted by  | Research

The University of Chicago and Johns Hopkins' Bloomberg~Kimmel Institute for Cancer Immunotherapy  have published a pair of studies looking at biomarkers involved in the immune system's response to tumors in the Nov. 7 issue of the Proceedings of the National Academy of Sciences. The University of Chicago studies are explained here. For the Johns Hopkins(...)

Do you have endocrinologists on the lung cancer team?

Posted by  | treatment

Endocrinologists, or hormone doctors, are on your lung cancer treatment team “if it's clinically appropriate for them to be a part of it,” says radiation oncologist Russell K. Hales, M.D. of the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus. Hales notes that “Endocrinologists often look at hormone levels, and we use(...)

What side effects can lung cancer radiation cause?

Posted by  | treatment

Many lung cancer patients are concerned about the side effects lung cancer radiation can cause, such as heart or kidney damage, or fertility problems, says radiation oncologist Russell K. Hales, M.D. of the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus. “Any therapy can cause short-term or long-term problems, and side effects,”(...)

A perspective on an immunotherapy clinical trial

Posted by  | Patient Stories

This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel Cancer Center. For more information on Kristina's story, watch her interview with Denise Grady on the New York Times' Facebook page or follow her on Twitter at @kristinabaum. For the post,(...)

How does diet affect lung cancer risk or treatment? Do you have a nutritionist on my care team?

Posted by  | Prevention/Screening, treatment

“When I meet with patients, I tell them that there are three critical parts to their therapy. The first is local therapy, such as surgery or radiation. The second is chemotherapy, or systemic therapy. And the third is their overall well-being, such as nutrition,” says Russell K. Hales, M.D. Hales, a radiation oncologist at the(...)

Johns Hopkins communications student honors father’s cancer battle in 5-mile swim

Johns Hopkins communications student honors father’s cancer battle in 5-mile swim

Posted by  | Patient Stories

Master of Health Communications student Brian Boyle will participate in this weekend's Swim Across America Baltimore event, which benefits the Johns Hopkins Kimmel Cancer Center. His father recently celebrated 25 years free of cancer and will be kayaking alongside his son in Sunday's swim event.  "Cancer has impacted our family many times, as it has for(...)

What Is Maryland’s Plan to Curb Cancer?

What Is Maryland’s Plan to Curb Cancer?

Posted by  | Uncategorized

We've heard much about the national Cancer Moonshot led by Vice President Joe Biden aimed at galvanizing resources across the nation to speed the rate of cancer discoveries. The Kimmel Cancer Center’s own deputy director, Elizabeth Jaffee, M.D., is co-chair of the national Cancer Moonshot’s Blue Ribbon Panel that has provided recommendations for the initiative. But on(...)